Publication:
Early Clinical Markers of Aggressive Multiple Sclerosis

dc.authorwosidSoysal, Aysun/Aax-7696-2021
dc.authorwosidLugaresi, Alessana/C-7743-2012
dc.authorwosidHorakova, Dana/D-4649-2011
dc.authorwosidLugaresi, Alessandra/C-7743-2012
dc.authorwosidTurkoglu, Recai/B-9336-2014
dc.authorwosidKubala Havrdova, Eva/P-4892-2017
dc.authorwosidSlee, Mark/J-4731-2015
dc.contributor.authorMalpas, Charles B.
dc.contributor.authorManouchehrinia, Ali
dc.contributor.authorSharmin, Sifat
dc.contributor.authorRoos, Izanne
dc.contributor.authorHorakova, Dana
dc.contributor.authorHavrdova, Eva Kubala
dc.contributor.authorKalincik, Tomas
dc.contributor.authorIDSoysal, Aysun/0000-0002-1598-5944
dc.contributor.authorIDMalpas, Charles/0000-0003-0534-3718
dc.contributor.authorIDLugaresi, Alessana/0000-0003-2902-5589
dc.contributor.authorIDVan Pesch, Vincent/0000-0003-2885-9004
dc.contributor.authorIDTurkoglu, Recai/0000-0001-9724-851X
dc.contributor.authorIDBoz, Cavit/0000-0003-0956-3304
dc.contributor.authorIDSlee, Mark/0000-0003-4323-2453
dc.date.accessioned2020-06-21T09:05:01Z
dc.date.available2020-06-21T09:05:01Z
dc.date.issued2020
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Malpas, Charles B.; Sharmin, Sifat; Roos, Izanne; Kalincik, Tomas] Univ Melbourne, Dept Med, CORe Unit, Melbourne, Vic, Australia; [Malpas, Charles B.; Sharmin, Sifat; Roos, Izanne; Kalincik, Tomas] Royal Melbourne Hosp, Dept Neurol, Melbourne, Vic, Australia; [Manouchehrinia, Ali] Karolinska Univ Hosp, Ctr Mol Med, Stockholm, Sweden; [Horakova, Dana; Havrdova, Eva Kubala] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Horakova, Dana; Havrdova, Eva Kubala] Gen Univ Hosp, Prague, Czech Republic; [Trojano, Maria] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy; [Izquierdo, Guillermo; Eichau, Sara] Hosp Univ Virgen Macarena, Seville, Spain; [Bergamaschi, Roberto] IRCCS Mondino Fdn, Pavia, Italy; [Sola, Patrizia; Ferraro, Diana] Azienda Osped Univ, Dept Neurosci, Modena, Italy; [Ferraro, Diana] Univ Modena & Reggio Emilia, Dept Biomed Metab & Neurosci, Modena, Italy; [Lugaresi, Alessandra] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Lugaresi, Alessandra] IRCCS, Ist Sci Neurol Bologna, Bologna, Italy; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] CHUM, Montreal, PQ, Canada; [Prat, Alexandre; Girard, Marc; Duquette, Pierre] Univ Montreal, Montreal, PQ, Canada; [Grammond, Pierre] CISSS Chaudiere Appalaches, Levis, PQ, Canada; [Grand'Maison, Francois] Neuro Rive Sud, Quebec City, PQ, Canada; [Ozakbas, Serkan] Dokuz Eylul Univ, Konak Izmir, Turkey; [Van Pesch, Vincent] Clin Univ St Luc, Brussels, Belgium; [Van Pesch, Vincent] Catholic Univ Louvain, Brussels, Belgium; [Granella, Franco] Univ Parma, Dept Med & Surg, Parma, Italy; [Hupperts, Raymond] Zuyderland Ziekenhuis, Sittard, Netherlands; [Pucci, Eugenio] Azienda Sanit Unica Regionale Marche AV3, UOC Neurol, Macerata, Italy; [Boz, Cavit] Farabi Hosp, KTU Med Fac, Trabzon, Turkey; [Sidhom, Youssef] Razi Hosp, Dept Neurol, Manouba, Tunisia; [Gouider, Riadh] Univ Tunis El Manar, Clin Invest Ctr Neurosci & Mental Hlth, Dept Neurol, Fac Med,Razi Hosp, LR 18SP03, Tunis, Tunisia; [Spitaleri, Daniele] Azienda Osped Rilievo Nazl San Giuseppe Moscati A, Avellino, Italy; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkey; [Petersen, Thor] Kommunehosp, Aarhus C, Denmark; [Verheul, Freek] Groene Hart Ziekenhuis, Gouda, Netherlands; [Karabudak, Rana] Hacettepe Univ, Ankara, Turkey; [Turkoglu, Recai] Haydarpasa Numune Training & Res Hosp, Istanbul, Turkey; [Ramo-Tello, Cristina] Hosp Badalona Germans Trias & Pujol, Badalona, Spain; [Terzi, Murat] 19 Mayis Univ, Med Fac, Samsun, Turkey; [Cristiano, Edgardo] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina; [Slee, Mark] Flinders Univ S Australia, Adelaide, SA, Australia; [McCombe, Pamela] Univ Queensland, Brisbane, Qld, Australia; [McCombe, Pamela] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Macdonell, Richard] Austin Hlth, Melbourne, Vic, Australia; [Fragoso, Yara] Univ Metropolitana Santos, Santos, SP, Brazil; [Olascoaga, Javier] Hosp Univ Donostia, Inst Invest Sanitaria Biodonostia, San Sebastian, Spain; [Altintas, Ayse] Koc Univ, Sch Med, Dept Neurol, Istanbul, Turkey; [Olsson, Tomas; Hillert, Jan] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Butzkueven, Helmut] Monash Univ, Cent Clin Sch, Melbourne, Vic, Australia; [Butzkueven, Helmut] Alfred Hosp, Dept Neurol, Melbourne, Vic, Australia; [Butzkueven, Helmut] Monash Univ, Dept Neurol, Box Hill Hosp, Melbourne, Vic, Australiaen_US
dc.descriptionSoysal, Aysun/0000-0002-1598-5944; Malpas, Charles/0000-0003-0534-3718; Lugaresi, Alessana/0000-0003-2902-5589; Van Pesch, Vincent/0000-0003-2885-9004; Turkoglu, Recai/0000-0001-9724-851X; Boz, Cavit/0000-0003-0956-3304; Kubala Havrdova, Eva/0000-0002-9543-4359; Trojano, Maria/0000-0002-6329-8946; Prat, Alexane/0000-0001-6188-0580; Gouider, Riadh/0000-0001-9615-3797; Ramo-Tello, Cristina/0000-0001-8643-5053; Olsson, Tomas/0000-0002-2938-1877; Petersen, Thor/0000-0001-5633-2600; Manouchehrinia, Ali/0000-0003-4857-5762; Roos, Izanne/0000-0003-0371-3666; Slee, Mark/0000-0003-4323-2453en_US
dc.description.abstractPatients with the 'aggressive' form of multiple sclerosis accrue disability at an accelerated rate, typically reaching Expanded Disability Status Score (EDSS) 5 6 within 10 years of symptom onset. Several clinicodemographic factors have been associated with aggressive multiple sclerosis, but less research has focused on clinical markers that are present in the first year of disease. The development of early predictive models of aggressive multiple sclerosis is essential to optimize treatment in this multiple sclerosis subtype. We evaluated whether patients who will develop aggressive multiple sclerosis can be identified based on early clinical markers. We then replicated this analysis in an independent cohort. Patient data were obtained from the MSBase observational study. Inclusion criteria were (i) first recorded disability score (EDSS) within 12 months of symptom onset; (ii) at least two recorded EDSS scores; and (iii) at least 10 years of observation time, based on time of last recorded EDSS score. Patients were classified as having 'aggressive multiple sclerosis' if all of the following criteria were met: (i) EDSS 5 6 reached within 10 years of symptom onset; (ii) EDSS 5 6 confirmed and sustained over 56 months; and (iii) EDSS 5 6 sustained until the end of follow-up. Clinical predictors included patient variables (sex, age at onset, baseline EDSS, disease duration at first visit) and recorded relapses in the first 12 months since disease onset (count, pyramidal signs, bowel-bladder symptoms, cerebellar signs, incomplete relapse recovery, steroid administration, hospitalization). Predictors were evaluated using Bayesian model averaging. Independent validation was performed using data from the Swedish Multiple Sclerosis Registry. Of the 2403 patients identified, 145 were classified as having aggressive multiple sclerosis (6%). Bayesian model averaging identified three statistical predictors: age 4 35 at symptom onset, EDSS 5 3 in the first year, and the presence of pyramidal signs in the first year. This model significantly predicted aggressive multiple sclerosis [area under the curve (AUC) = 0.80, 95% confidence intervals (CIs): 0.75, 0.84, positive predictive value = 0.15, negative predictive value = 0.98]. The presence of all three signs was strongly predictive, with 32% of such patients meeting aggressive disease criteria. The absence of all three signs was associated with a 1.4% risk. Of the 556 eligible patients in the Swedish Multiple Sclerosis Registry cohort, 34 (6%) met criteria for aggressive multiple sclerosis. The combination of all three signs was also predictive in this cohort (AUC = 0.75, 95% CIs: 0.66, 0.84, positive predictive value = 0.15, negative predictive value = 0.97). Taken together, these findings suggest that older age at symptom onset, greater disability during the first year, and pyramidal signs in the first year are early indicators of aggressive multiple sclerosis.en_US
dc.description.sponsorshipNational Health and Medical Research Council of Australia [1129189, 1140766, 1157717]; Merck; Bayer Schering; Sanofi Genzyme; Teva; Roche; Biogen; Novartis; National Health and Medical Research Council of Australia [1157717] Funding Source: NHMRCen_US
dc.description.sponsorshipThis study was financially supported by the National Health and Medical Research Council of Australia (1129189, 1140766, 1157717). The MSBase Foundation is a not-forprofit organization that receives support from Roche, Merck, Biogen, Novartis, Bayer Schering, Sanofi Genzyme and Teva. The study was conducted separately and apart from the guidance of the sponsors.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1093/brain/awaa081
dc.identifier.endpage1413en_US
dc.identifier.issn0006-8950
dc.identifier.issn1460-2156
dc.identifier.issue5en_US
dc.identifier.pmid32386427
dc.identifier.scopusqualityQ1
dc.identifier.startpage1400en_US
dc.identifier.urihttps://doi.org/10.1093/brain/awaa081
dc.identifier.volume143en_US
dc.identifier.wosWOS:000541777000023
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofBrainen_US
dc.relation.journalBrain : a journal of neurologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMultiple Sclerosisen_US
dc.subjectPredictionen_US
dc.subjectDisabilityen_US
dc.subjectAggressive Diseaseen_US
dc.subjectPrecision Medicineen_US
dc.titleEarly Clinical Markers of Aggressive Multiple Sclerosisen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files